Is there adequate provision of venous thrombo-embolism prophylaxis following hip arthroplasty? An audit and international survey
Open Access
- 1 November 2010
- journal article
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 92 (8), 668-672
- https://doi.org/10.1308/003588410x12699663904952
Abstract
INTRODUCTION The peak incidence of venous thrombo-embolism (VTE) occurs 3 weeks following hip arthroplasty surgery and current guidelines proposing VTE prophylaxis continuing for 4 weeks after surgery. This study first compares the duration of treatment and satisfaction between patients prescribed low molecular weight heparin (LMWH) and rivaroxaban, a new oral Factor Xa inhibitor, following elective hip arthroplasty; and second, surveys the duration of LMWH use in other units. SUBJECTS AND METHODS An international survey detailing the use of LMWH was performed. A prospective audit was performed of 100 hip replacements, with 50 prescribed 40 mg once daily of subcutaneous enoxaparin and subsequently 50 patients prescribed 10 mg once daily of oral rivaroxaban. The duration of treatment, patient satisfaction and complications for both cohorts was quantified and compared against published evidence-based guidelines. RESULTS The survey demonstrated that four out of 39 (10.2%) units that routinely prescribe LMWH do so for at least 4 weeks following surgery. The audit demonstrated that rivaroxaban afforded a superior mean duration of postoperative VTE prophylaxis (35 days vs 5.4 days; P < 0.05) and superior patient satisfaction. There was no difference in the incidence of bleeding, wound infection or thrombotic complications. CONCLUSIONS This study demonstrates that patients are exposed to an increased VTE risk following hip replacement surgery due to the inadequate prescription of LMWH. This is poor clinical practice, contrary to current evidence-based guidelines and has potential medicolegal implications. The prescription of rivaroxaban affords a superior patient compliance compared with subcutaneous LMWH, thus ensuring that patients receive VTE prophylaxis for the current recommend period of time.Keywords
This publication has 35 references indexed in Scilit:
- Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guidelineHeart, 2010
- Busy times aheadBulletin of The Royal College of Surgeons of England, 2010
- The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limbThe Journal of Bone and Joint Surgery. British volume, 2010
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 2008
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic eventsThe Journal of Bone and Joint Surgery. British volume, 2007
- Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidanceBMJ, 2007
- The Mark Coventry Award: Prevention of Readmission for Venous Thromboembolism after Total Knee ArthroplastyPublished by Ovid Technologies (Wolters Kluwer Health) ,2006
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004
- Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analysesBritish Journal of Surgery, 1997